Patents by Inventor Helene-Celine Huguet

Helene-Celine Huguet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130190278
    Abstract: The present invention relates to the use of the compounds of formula (I) and their pharmaceutically acceptable salts for the treatment or the prevention of ocular inflammatory diseases, in particular for the treatment and/or prevention of uveitis, severe conjunctivitis, dry eye syndrome or diabetic retinopathy.
    Type: Application
    Filed: July 8, 2011
    Publication date: July 25, 2013
    Applicant: Laboratoires Fournier SA
    Inventors: Jocelyne Annat, Hélène-Céline Huguet, Olivier Lacombe, Luc Lebreton
  • Patent number: 8388984
    Abstract: Compositions which deliver adsorbents, alone or in combination with active drug “degrading molecules,” in a site-specific manner to the intestine, and which eliminate or at least lower the concentration of residual unwanted material within the intestine, and methods of treatment using the compositions, are disclosed. The compositions are ideally designed to specifically release the adsorbents in a programmed manner at a specific site of the intestinal tract. Programmed delivery prevents adsorbents from interfering with the normal absorption process of a given molecule after oral absorption, until it reaches the lower part of the small intestine. The compositions can be used to adsorb, and therefore remove, any residual drug, metabolite thereof, or bacterial toxin after oral or parenteral administration which would otherwise cause adverse effects in the lower intestine and/or colon.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: March 5, 2013
    Assignees: Da Volterra, Centre National de la Recherche Scientifique, Assistance Publique—Hopitaux de Paris, Universite Paris Diderot—Paris 7, Universite Paris-SUD 11
    Inventors: Helene-Celine Huguet, Antoine Andremont, Nicolas Tsapis, Elias Fattal
  • Publication number: 20120107367
    Abstract: Compositions which deliver adsorbents, alone or in combination with active drug “degrading molecules,” in a site-specific manner to the intestine, and which eliminate or at least lower the concentration of residual unwanted material within the intestine, and methods of treatment using the compositions, are disclosed. The compositions are ideally designed to specifically release the adsorbents in a programmed manner at a specific site of the intestinal tract. Programmed delivery prevents adsorbents from interfering with the normal absorption process of a given molecule after oral absorption, until it reaches the lower part of the small intestine. The compositions can be used to adsorb, and therefore remove, any residual drug, metabolite thereof, or bacterial toxin after oral or parenteral administration which would otherwise cause adverse effects in the lower intestine and/or colon.
    Type: Application
    Filed: September 14, 2011
    Publication date: May 3, 2012
    Inventors: Helene-Celine Huguet, Antoine Andremont, Nicolas Tsapis, Elias Fattal
  • Patent number: 8106000
    Abstract: Orally administrable, site-specific (colonic), particulate delivery systems including adsorbents are disclosed. When delivered specifically to the colon, they can remove various substances present in, or as they reach, the colon. Methods of treatment using the delivery systems, and methods of preparing the delivery systems, are also disclosed. The particulate delivery systems are based on adsorbent matrices encapsulated into and/or onto particles, which selectively deliver the adsorbents to the colon. Representative drug delivery devices include pectin beads, which can optionally be crosslinked with metal ions such as zinc and/or calcium. The delivery system protects the adsorbent and prevents its adsorbing effect in the upper gastro-intestinal (GI) tract. When the particles are made from pectin, and the beads are administered to the colon, specific pectinolytic enzymes in the colon degrade the pectin, allowing the adsorbent to be released and to be fully active.
    Type: Grant
    Filed: May 18, 2006
    Date of Patent: January 31, 2012
    Assignee: Da Volterra
    Inventors: Helene-Celine Huguet, Elias Fattal, Antoine Andremont, Nicolas Tsapis
  • Publication number: 20090324568
    Abstract: Orally administrable, site-specific (colonic), particulate delivery systems including adsorbents are disclosed. When delivered specifically to the colon, they can remove various substances present in, or as they reach, the colon. Methods of treatment using the delivery systems, and methods of preparing the delivery systems, are also disclosed. The particulate delivery systems are based on adsorbent matrices encapsulated into and/or onto particles, which selectively deliver the adsorbents to the colon. Representative drug delivery devices include pectin beads, which can optionally be crosslinked with metal ions such as zinc and/or calcium. The delivery system protects the adsorbent and prevents its adsorbing effect in the upper gastro-intestinal (GI) tract. When the particles are made from pectin, and the beads are administered to the colon, specific pectinolytic enzymes in the colon degrade the pectin, allowing the adsorbent to be released and to be fully active.
    Type: Application
    Filed: May 18, 2006
    Publication date: December 31, 2009
    Inventors: Helene-Celine Huguet, Elias Fattal, Antoine Andremont, Nicolas Tsapis